



## NexImmune Management to Present at Upcoming Conferences

December 2, 2019

**GAITHERSBURG, MD -- December 02, 2019** – NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, NexImmune's Chief Executive Officer, will be participating and presenting a corporate update at the following conferences. A webcast of Wednesday's presentation will be available on the Company's website under the News & Events tab.

### **Piper Jaffray's 31<sup>st</sup> Annual Healthcare Conference**

Tuesday, December 3<sup>rd</sup>, 3:50PM ET  
New York, NY

### **Evercore's 2<sup>nd</sup> Annual HealthCONx Conference**

Wednesday, December 4<sup>th</sup>, 3:50PM ET  
Boston, MA

## About NexImmune

NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on the proprietary Artificial Immune Modulation (AIM) nanotechnology platform. The AIM platform enables the ability to expand multi-antigen specific T cells with enhanced anti-tumor properties without the need for genetic manipulation. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer and auto-immune diseases.

The AIM platform is comprised of two core components: (1) a synthetic nanoparticle that functions as an artificial antigen presenting cell (aAPC) to prime and activate T cells directed at multiple tumor antigen targets across a broad range of both solid and hematologic malignancies; and (2) a proprietary T cell enrichment and expansion (E&E) process that controls ex vivo T cell proliferation and subtype differentiation. In preclinical experiments, the AIM system demonstrated the ability to enhance naturally occurring tumor cell recognition, engagement and signaling mechanisms that increased the anti-tumor potency, target specific killing and long-term durability of endogenous cytolytic T-cells. Utilizing natural target recognition and killing mechanisms may also reduce the potential for alloreactive toxicities observed with genetically engineered T cell therapies. The Company's aAPCs have also demonstrated potential utility as both injectable and cellular therapeutic agents.

For more information visit: [www.neximmune.com](http://www.neximmune.com)

## Contact

Chad Rubin  
Solebury Trout  
[crubin@soleburytrout.com](mailto:crubin@soleburytrout.com)  
+1-646-378-2947